Kinetic analysis of integrin-dependent cell adhesion on vitronectin--the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides
- PMID: 9654064
- DOI: 10.1046/j.1432-1327.1998.2530669.x
Kinetic analysis of integrin-dependent cell adhesion on vitronectin--the inhibitory potential of plasminogen activator inhibitor-1 and RGD peptides
Abstract
Distinct binding interactions between cell-surface receptors and extracellular matrix components are characteristic of multifunctional adhesion proteins such as vitronectin. The close proximity of binding sites for alpha(v)-integrins and plasminogen activator inhibitor-1 (PAI-1) on vitronectin may have consequences for cell adhesion and migration, or for the localized inhibition of plasminogen activators. In this study, the kinetics and reversibility of vitronectin-dependent cell adhesion via alpha(v)-integrins was investigated using RGD peptides and PAI-1 as competitors. Active, but not latent or cleaved PAI-1, and RGD peptides were effective in preventing cell adhesion to vitronectin provided the inhibitor was present at the time of cell seeding. In a concentration-dependent manner urokinase or thrombin abrogated the inhibitory effect of PAI-1. Following cell seeding onto a vitronectin substratum, delayed addition of RGD peptides or active PAI-1 (10-20 min post-seeding) resulted in the loss of their inhibitory potential. These data were supported by experiments in a purified system where delayed addition of active PAI-1 could no longer prevent vitronectin binding to immobilized alpha(v)beta3, while a cyclic RGD peptide gave some moderate inhibition. The apparent stabilization of vitronectin-integrin contacts was observed with immobilized native or multimeric vitronectin but not with the more rigid form of denatured, aggregated multimers. These results demonstrate that the cell adhesive properties of vitronectin depend on its conformational flexibility and can be tightly regulated in a spatio-temporal manner through direct competition of cellular integrins by soluble or matrix-bound factors such as PAI-1.
Similar articles
-
Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation.Exp Cell Res. 1997 May 1;232(2):420-9. doi: 10.1006/excr.1997.3540. Exp Cell Res. 1997. PMID: 9168821
-
Binding of urokinase to plasminogen activator inhibitor type-1 mediates cell adhesion and spreading.J Cell Sci. 1997 May;110 ( Pt 9):1091-8. doi: 10.1242/jcs.110.9.1091. J Cell Sci. 1997. PMID: 9175705
-
Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin.J Cell Physiol. 2001 Oct;189(1):23-33. doi: 10.1002/jcp.1133. J Cell Physiol. 2001. PMID: 11573201
-
Vitronectin.Int J Biochem Cell Biol. 1999 May;31(5):539-44. doi: 10.1016/s1357-2725(99)00005-9. Int J Biochem Cell Biol. 1999. PMID: 10399314 Review.
-
Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn.Biol Chem. 2002 Jul-Aug;383(7-8):1143-9. doi: 10.1515/BC.2002.125. Biol Chem. 2002. PMID: 12437099 Review.
Cited by
-
Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vitro.Clin Exp Metastasis. 2000;18(6):445-53. doi: 10.1023/a:1011882421528. Clin Exp Metastasis. 2000. PMID: 11592301
-
A phase I study of continuous infusion cilengitide in patients with solid tumors.Invest New Drugs. 2012 Apr;30(2):604-10. doi: 10.1007/s10637-010-9537-9. Epub 2010 Sep 14. Invest New Drugs. 2012. PMID: 20839028 Free PMC article. Clinical Trial.
-
Integrin alphavbeta3, requirement for VEGFR2-mediated activation of SAPK2/p38 and for Hsp90-dependent phosphorylation of focal adhesion kinase in endothelial cells activated by VEGF.Cell Stress Chaperones. 2003 Spring;8(1):37-52. doi: 10.1379/1466-1268(2003)8<37:ivrfva>2.0.co;2. Cell Stress Chaperones. 2003. PMID: 12820653 Free PMC article.
-
Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.J Clin Oncol. 2007 May 1;25(13):1651-7. doi: 10.1200/JCO.2006.06.6514. J Clin Oncol. 2007. PMID: 17470857 Free PMC article. Clinical Trial.
-
Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer.Invest New Drugs. 2013 Feb;31(1):175-82. doi: 10.1007/s10637-012-9842-6. Epub 2012 Jul 3. Invest New Drugs. 2013. PMID: 22752690 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous